Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease

BackgroundAbnormalities of fibroblast growth factor-23 (FGF-23) plasma levels predict adverse outcomes in patients with coronary artery disease. However, FGF-23 has a different behaviour in the presence of type 2 diabetes mellitus (T2D). We explored whether the presence of T2D affects the predictive power of FGF-23. MethodsIn 704 patients with stable coronary artery disease, FGF-23, calcidiol, parathormone (PTH) and phosphate plasma levels were prospectively assessed. The primary outcome was the development of acute ischemic events (acute coronary syndrome, stroke or transient ischemic attack), heart failure or death. ResultsOne hundred seventy-three (24.6%) patients had T2D, without differences in age, sex or estimated glomerular filtration rate as compared with non-diabetic patients. Serum PTH was lower and phosphate higher in T2D than in non-diabetic patients, without differences in FGF-23 or calcidiol levels. During follow-up (2.150.99years), 26 (15.2%) T2D and 51 (9.6%) non-diabetic patients developed the outcome (p=0.048). T2D patients who developed the outcome had higher FGF-23 [112.0 (59.9, 167.6) vs 68.9 (54.2, 93.0) RU/mL; p=0.002], PTH [71.3 (47.3, 106.6) vs 51.9 (40.8, 66.2) pg/mL; p=0.004) and phosphate (3.530.71 vs 3.25 +/- 0.50mg/dL; p=0.017) levels than T2D subjects who remained stable. These differences were not significant in non-diabetic patients. p id=dmrr2787-para-0005By multivariable Cox proportional hazard model, FGF-23 predicted independently the outcome in T2D patients [hazard ratio=1.277; 95% CI (1.132, 1.442)] but not in those without T2D. Conclusionsp id=dmrr2787-para-0006FGF-23 plasma levels predict adverse cardiovascular outcomes in coronary artery disease patients who have T2D but not in those without T2D. This finding should be confirmed in larger studies. Copyright (c) 2016 John Wiley & Sons, Ltd.